Biotech Values

[bellweather1]

TGTX/TGR-1202

Tony,

See I forgot to mention that the TGR-1202 formulation and tx regimen has been tweaked so that administering this PI3Kdelta while taking food and reducing particle size was shown to increase exposure level 3-4fold(as previously mentioned by BTH)-and this is on top of their already very competitive and safe performance(based on the previous regimen)reported last night-

This suggests TGR-1202 has great best in class potential, which by itself more than justifies a much higher valuation than tgtx currently has.

However, the real icing on the cake should come when tgtx report it's own proprietary first combo data(TGR-1202 & TG-1101) in B Cell Malignancies next month. I'm willing to bet you'll see great efficacy w/o serious side effects, which will be a big improvement over the Gilead Syk/Idelalisib combo data from last night(trial stoppage due to 5 deaths and excessive AEs)...

Best Regards,

bw